Tratamiento de pacientes con la COVID-19, con el anticuerpo itolizumab (anti-CD6)

Tatiana Hernández Casola, Rodolfo Vega Candelario

Texto completo:



Tratamiento de pacientes con la COVID-19, con el anticuerpo itolizumab (anti-CD6)

Palabras clave

COVID-19; SARS-CoV-2; síndrome de liberación de citoquinas


Roshni Menon, Brinda G David. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology. Pondicherry, India. 2015 [acceso: 20/03/2019]; 8:215-22. Disponible en:

Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological wea-pon. Ann Transl Med. 2020;8(11):693. DOI: 10.21037/atm-20-3989.

Gore V, Kshirsagar DP, Bhat SM. Itolizumab treatment for cytokine release syndrome in moderate to severe acute respiratory distress syndrome due to COVID-19: clinical outcomes, a retrospective study. J Assoc Physicians India. 2021; 69:43-48. DOI: 10. covidwho-1161613

Thacker HP, Halnor D, Dhekane A, Wadhwa N, Patil S, Gandhi B, et al. An early experience of Itolizumab with best supportive care in the treatment of moderate to severe COVID-19 patients: A retrospective study. IP Indian J Immunol Respir Med.2021; 6(1):24-8. DOI: 10.18231/j.ijirm.2021.005

Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med. 2020; 34:223-31. DOI: 10.1007/s40290-020-00342-z

Chen X, Zhao B, Qu Y.Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis.2020; 71(8):1937-42. DOI: 10.1093/cid/ciaa449

Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. IL-6: relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020; 53:13-24. DOI: 10.1016/j.cytogfr.2020.05.009

Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci 2018; 19:1442. DOI: 10.1016/j.cytogfr.2020.05.009

Stone JH, Frigault MJ, Serling-Boyd NJ. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020; 383(24):2333-44. DOI: 10.1056/NEJMoa2028836

Enlaces refback

  • No hay ningún enlace refback.

URL de la licencia: